Intellia Therapeutics (NTLA) Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Assets data on file, last reported at $466.4 million in Q1 2026.

• Quarterly Current Assets fell 15.41% year-over-year to $466.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466.4 million (down 15.41% YoY) and the FY2025 annual result came in at $527.7 million, down 17.53% from the prior year.
• Current Assets slipped to $466.4 million in Q1 2026 per NTLA's latest filing, from $527.7 million in the prior quarter.
• Across five years, Current Assets topped out at $1.2 billion in Q4 2022 and bottomed at $466.4 million in Q1 2026.
• The 5-year median for Current Assets is $858.9 million (2022), against an average of $779.8 million.
• The widest annual swing landed in 2022, when Current Assets surged 62.98%; it then plunged 37.63% in 2025.
• Tracing NTLA's Current Assets over 5 years: stood at $1.2 billion in 2022, then retreated by 17.95% to $998.3 million in 2023, then sank by 35.91% to $639.9 million in 2024, then decreased by 17.53% to $527.7 million in 2025, then dropped by 11.61% to $466.4 million in 2026.
• Per Business Quant, the three latest NTLA Current Assets figures stand at $466.4 million (Q1 2026), $527.7 million (Q4 2025), and $581.9 million (Q3 2025).

Peer Comparison